Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCP: Continuous vs Pulsed PEG-IFN-α2b in Chronic Hepatitis B
NCT05922306Phase 1Recruiting
- Sponsor
- Anhui Medical University
- Start
- Jul 2023
- Primary completion
- Jun 2027
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by Anhui Medical University. Primary endpoints: HBsAg negative conversion rate at 96 weeks and HBsAb conversion rate at 96 weeks. Started Jul 2023; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05922306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922306.